Atogepant open label data support long term efficacy and safety Sustained response to eptinezumab over 18 months Fresh insights on CGRP mAb and gepant prescribing New data support central action for fremanezumab and ubrogepant Zavegepant reduces need for analgesics AHS recommends anti-CGRP therapies as first line for migraine prevention Imaging data support central effects of erenumab Additive effects of multiple anti-CGRP therapies seen on CGRP-induced vasorelaxation

Rimegepant

Rimegepant

In February 2020, Nurtec ODT (rimegepant) became the second oral CGRP receptor antagonist (gepant) to be approved for the acute treatment of migraine in adults. Rimegepant is formulated as a fast-acting orally disintegrating tablet (ODT), and its approval was supported by data including results of the Phase 3 Study 303 of rimegepant ODT, and additional clinical trials of rimegepant tablet including Study 301 and Study 302.

Download slideset »

« back to Slides

Educational Partners and Supporters

Lilly

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |